A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2: MRD Negative CR Rate

MRDnegCR rate, is defined as the percentage of participants who have achieved sCR or CR and have negative MRD defined at 10\^-5 threshold as assessed by NGS.

Time frame: Up to Approximately 52 Weeks

Phase 2: PFS

PFS is defined as the duration from the date of randomization to the date of confirmed disease progression (PD) determined by IRC per IMWG (2016) response criteria, or death, whichever occurs first.

Time frame: Up to Approximately 130 Months

Phase 2: Sustained MRD Negativity Rate

The rate of sustained MRD-negativity is defined as the percentage of participants with maintenance of MRD negativity status in bone marrow confirmed \>=12 months apart prior to initiation of new anti-MM therapy.

Time frame: Up to Approximately 12 Months

Phase 2: Area Under the Serum Concentration-Time Curve (AUC)

Area under the plasma concentration-time curve (AUC).

Time frame: Up to Approximately 12 Months

Phase 2: Overall Survival (OS)

OS is defined as the duration from the date of randomization to the date of the participant's death.

Time frame: Up to Approximately 16 Years

Phase 2: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability

Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs)

Time frame: Up to Approximately 16 Years

Phase 2: Maximum Observed Serum Concentration (Cmax)

Maximum observed serum concentration (Cmax).

Time frame: Up to Approximately 12 Months

Phase 2: Time to Cmax (Time to Maximum Observed Concentration, Tmax)

Time to Cmax.

Time frame: Up to Approximately 12 Months

Phase 2: Positive Anti-Drug Antibodies (ADAs)

Positive ADAs.

Time frame: Up to Approximately 90 days after the last dose of study treatment

Phase 2: Negative ADAs

Negative ADAs.

Time frame: Up to Approximately 90 days after the last dose of study treatment

Phase 2: Neutralizing Anti-Drug Antibodies (NAbs)

Neutralizing anti-drug antibodies (NAbs).

Time frame: Up to Approximately 90 days after the last dose of study treatment

Phase 3: OS

OS is defined as the duration from the date of randomization to the date of the participant's death.

Time frame: Up to Approximately 16 Years

Phase 3: Sustained MRD Negativity Rate

The rate of sustained MRD-negativity is defined as the percentage of participants with maintenance of MRD negativity status in bone marrow confirmed \>=12 months apart prior to initiation of new anti-MM therapy.

Time frame: Up to Approximately 12 Months

Phase 3: Rate of >= CR

The rate of \>= CR is defined as the percentage of participants who achieve a sCR or CR determined by IMWG (2016) response criteria, per IRC assessment, prior to the initiation of new anti-myeloma therapy.

Time frame: Up to Approximately 12 Months

Phase 3: Rate of >= VGPR or Better

The rate of \>= VGPR is defined as the percentage of participants who achieve a VGPR or better determined by IMWG (2016) response criteria, per IRC assessment, prior to the initiation of new anti-myeloma therapy.

Time frame: Up to Approximately 12 Months

Phase 3: ORR

ORR is defined as percentage of participants with a response of PR or better per IMWG criteria.

Time frame: Up to Approximately 52 Weeks

Phase 3: Time to Response (TTR)

TTR is defined as the number of months from the date of randomization to the date of best overall response of CR or PR ('responders') determined by IMWG criteria as assessed by investigator.

Time frame: Up to Approximately 12 Months

Phase 3: Duration of Response (DOR)

DOR is defined as the number of days from the day the response criteria are met to the date that disease progression.

Time frame: Up to Approximately 16 Years

Phase 3: Time-to-Progression (TTP)

Time to progression is defined as the number of days from the date of randomization to the date of the first documented disease progression or relapse.

Time frame: Up to Approximately 16 Years

Phase 3: Event Free Survival (EFS)

EFS will be measured as the number of days between the initiation of the subsequent anticancer therapy and disease progression, or refractory disease, or death.

Time frame: Up to Approximately 16 Years

Phase 3: Progression-Free Survival on Subsequent Therapy (PFS2)

PFS2 is defined as the duration from the date of randomization to the date of confirmed disease progression on the next line of therapy or death, whichever occurs first

Time frame: Up to Approximately 16 Years

Phase 3: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability

Incidence, severity, seriousness, and causality of TEAEs

Time frame: Up to Approximately 16 Years

Phase 3: Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Functioning Score

The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Subjects rate items on a 4- point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).

Time frame: Up to Approximately 16 Years

Phase 3: Change from Baseline in EORTC QLQ-C30 Global Health Status/QoL Score

The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Subjects rate items on a 4- point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).

Time frame: Up to Approximately 16 Years

Phase 3: Change from Baseline and Time to Deterioration in the Remaining Scales and Items of EORTC QLQ-C30

The EORTC QLQ-C30 is a 30-item patient-reported questionnaire composed of both multi-item and single scales including 5 functional scales (physical, role, emotional, social, and cognitive), 3 symptom scales (fatigue, nausea and vomiting, and pain), a global health status/QoL scale, and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Subjects rate items on a 4- point scale ranging from 1 to 4 (1 = Not at All, 2 = A Little, 3 = Quite a Bit, and 4 = Very Much).

Time frame: Up to Approximately 16 Years

Phase 3: Symptomatic AEs as Assessed by the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the CTCAE. PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present).

Time frame: Up to Approximately 16 Years

Phase 3: Overall Bother Due to Treatment Side Effects as Assessed by the Functional Assessment of Cancer Therapy-General (FACT-G) GP5

The FACT-G GP5 Item is a part of the FACT-G which is a 27-item questionnaire that measures four domains of health-related quality of life (HRQOL) in cancer patients: physical, social, emotional and functional well-being. The FACT-G GP5 item ("I am bothered by side effects of treatment") is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on patients. This item is rated on a 5-point Likert scale from "not at all" to "very much.".

Time frame: Up to Approximately 16 Years

Phase 3: Change from Baseline in Patient Global Impression of Severity (PGIS) Scores

The PGIS scale asks the patient to assess their overall QoL, as well as difficulty of doing physical activities due to MM over the past 7 days. Each item employs a 5-point Likert scale from "not at all" to "very much."

Time frame: Up to Approximately 16 Years

Phase 3: Change from Baseline in European Quality of Life 5 Dimensions (EQ-5D-5L) Scores

The EQ-5D descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems.

Time frame: Up to Approximately 16 Years